United Therapeutics Expands Regen Med Platform with $300 Million Acquisition of Thymus Therapy

Rare Daily Staff

United Therapeutics is deepening its push into regenerative medicine and immune system engineering with the acquisition of privately held Thymmune Therapeutics for up to $300 million.

United will pay $140 million in upfront cash and up to $160 million in milestone-based earnouts tied to clinical and regulatory progress through 2031.

The acquisition underscores a growing convergence between regenerative medicine and immunology, particularly in efforts to induce durable immune tolerance without chronic immunosuppression. While thymus-based therapies have long been explored in academic settings, scalable iPSC-derived approaches remain largely unproven in humans, placing THY-100 firmly in high-risk, high-reward territory. For United Therapeutics, the move reflects its ongoing willingness to invest early in platform technologies that could reshape transplant medicine and potentially redefine how immune function is restored.

Thymmune, a preclinical-stage biotech, is developing induced pluripotent stem cell–derived thymic cell therapies designed to restore immune function by rebuilding or replacing the thymus—a central organ in T-cell development that deteriorates with age or is absent in certain rare conditions.

The company’s lead asset, THY-100, targets congenital athymia, an ultra-rare and often fatal pediatric disorder in which infants are born without a functional thymus. Preclinical studies suggest the therapy can generate a functional “neo-thymus” in vivo, enabling T-cell maturation.

United Therapeutics CEO Martine Rothblatt framed the acquisition as a strategic extension of the company’s broader transplant and organ replacement ambitions, including its UThymoKidney program, which combines engineered organs with immune tolerance strategies. “By restoring or modulating T-cell receptor diversity, Thymmune’s technology could address the root causes of numerous life-threatening diseases,” Rothblatt said in the announcement.

Beyond rare disease, the company sees broader applications for thymic regeneration, including transplant tolerance, autoimmune disorders, and potentially age-related immune decline—a category that has drawn increasing interest as immunosenescence is increasingly recognized as a driver of morbidity.

Photo: United Therapeutics CEO Martine Rothblatt